Abstract
Purpose
Anaplastic lymphoma kinase (ALK) mutations occurs in approximately 3–5% of patients with non-small cell lung cancer (NSCLC). Pleural involvement/effusion is common in ALK-positive patients with NSCLC at baseline. The aim of the study was to evaluate the characteristics of ALK-positive patients who have Ple-I/E.
Methods
In this multicenter study, patients with ALK-positive NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median progression-free survival (PFS), and overall survival (OS) were evaluated in 362 ALK-positive patients with NSCLC.
Results
Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (range 21–85) years. All patients’ histology was adenocarcinoma (100%). At baseline, 57 (15.7%) patients had Ple-I/E. There was no association between Ple-I/E and gender, lung metastasis, or distant lymphadenopathy (LAP) metastasis. The frequencies of liver, brain, and bone metastases were significantly higher in ALK-positive patients without Ple-I/E compared to those with Ple-I/E (respectively 18.2% vs 4.8%, p = 0.008; 19.1% vs 4.8%, p = 0.001; 20.6% vs 8.9%, p = 0.002). The median PFS was longer in ALK-positive patients who had Ple-I/E (18.7 vs 10.6 months, p = 0.017). Similarly, the median OS was longer in ALK-positive patients who had Ple-I/E (44.6 vs 22.6 months, p = 0.051).
Conclusion
Brain, liver, and bone metastases were lower in ALK-positive patients with Ple-I/E. Patients presented with Ple-I/E were prone to have better PFS and OS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Zalcman G (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387(10026):1415–1426. https://doi.org/10.1016/s0140-6736(16)00004-0
Bilgin B, Şendur MAN, Yücel Ş, Hizal M, Güner G, Akyürek N, Erol C, Akıncı MB, Dede D, Yalçın B, Kılıçkap S (2021) The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement. J Cancer Res Clin Oncol 147(9):2637–2643. https://doi.org/10.1007/s00432-021-03546-1
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Popat S (2020) Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol 38(31):3592–3603. https://doi.org/10.1200/jco.20.00505
Campos-Balea B, de Castro Carpeño J, Massutí B, Vicente-Baz D, Pérez Parente D, Ruiz-Gracia P, Crama L, Cobo Dols M (2020) Prognostic factors for survival in patients with metastatic lung adenocarcinoma: an analysis of the SEER database. Thoracic Cancer 11(11):3357–3364. https://doi.org/10.1111/1759-7714.13681
Chen G, Chen X, Zhang Y, Yan F, Fang W, Yang Y, Hong S, Miao S, Wu M, Huang X, Luo Y, Zhou C, Gong R, Huang Y, Zhou N, Zhao H, Zhang L (2017) A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer. Cancer Med 6(5):953–961. https://doi.org/10.1002/cam4.1059
Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita Y, Sugiyama Y, Ishikawa Y, Mano H (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68(13):4971–4976. https://doi.org/10.1158/0008-5472.Can-07-6158
Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588–1594. https://doi.org/10.1002/(sici)1097-0142(19971015)80:8+%3c1588::aid-cncr9%3e3.3.co;2-z
Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner DL, Varella-Garcia M, Camidge DR (2012) Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 118(18):4502–4511. https://doi.org/10.1002/cncr.27409
Dragoj M, Milosevic Z, Bankovic J, Tanic N, Pesic M, Stankovic T (2017) Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma. Cell Oncol (dordr) 40(1):47–62. https://doi.org/10.1007/s13402-016-0304-6
Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986) Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 4(5):702–709. https://doi.org/10.1200/jco.1986.4.5.702
Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75(1):5–14. https://doi.org/10.1007/s11060-004-8093-6
Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R (2019) Anaplastic Lymphoma Kinase (ALK)-positive tumors: clinical, radiographic and molecular profiles, and uncommon sites of metastases in patients with lung adenocarcinoma. Am J Clin Oncol 42(4):337–344. https://doi.org/10.1097/coc.0000000000000508
Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH (2005) Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 23(1):175–183. https://doi.org/10.1200/jco.2005.04.177
Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN (2016) Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34(2):123–129. https://doi.org/10.1200/jco.2015.62.0138
Li J, Zhu H, Sun L, Xu W, Wang X (2019) Prognostic value of site-specific metastases in lung cancer: a population based study [Research Paper]. J Cancer 10(14):3079–3086. https://doi.org/10.7150/jca.30463
Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69(1–2):1–18. https://doi.org/10.1016/s0304-3959(96)03267-8
Nakagawa T, Okumura N, Ohata K, Igai H, Matsuoka T, Kameyama K (2008) Postrecurrence survival in patients with stage I non-small cell lung cancer. Eur J Cardiothorac Surg 34(3):499–504. https://doi.org/10.1016/j.ejcts.2008.05.016
Onuigbo WI (1974) Contralateral pulmonary metastases in lung cancer. Thorax 29(1):132–133. https://doi.org/10.1136/thx.29.1.132
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, Ou S-HI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T (2017) Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med 377(9):829–838. https://doi.org/10.1056/NEJMoa1704795
Pikor LA, Ramnarine VR, Lam S, Lam WL (2013) Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer 82(2):179–189. https://doi.org/10.1016/j.lungcan.2013.07.025
Quint LE, Tummala S, Brisson LJ, Francis IR, Krupnick AS, Kazerooni EA, Iannettoni MD, Whyte RI, Orringer MB (1996) Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 62(1):246–250. https://doi.org/10.1016/0003-4975(96)00220-2
Rizzo S, Petrella F, Buscarino V, De Maria F, Raimondi S, Barberis M, Fumagalli C, Spitaleri G, Rampinelli C, De Marinis F, Spaggiari L, Bellomi M (2016) CT Radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol 26(1):32–42. https://doi.org/10.1007/s00330-015-3814-0
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ (2020) First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383(21):2018–2029. https://doi.org/10.1056/NEJMoa2027187
Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E (2017) Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18(7):874–886. https://doi.org/10.1016/s1470-2045(17)30339-x
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. https://doi.org/10.3322/caac.21208
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S-I, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566. https://doi.org/10.1038/nature05945
Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167–2177. https://doi.org/10.1056/NEJMoa1408440
Sørensen JB, Hansen HH, Hansen M, Dombernowsky P (1988) Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6(9):1474–1480. https://doi.org/10.1200/jco.1988.6.9.1474
Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Pass HI (2016) Scientific advances in lung cancer 2015. J Thorac Oncol 11(5):613–638. https://doi.org/10.1016/j.jtho.2016.03.012
Varella-Garcia MIJ, Pao W (2011) ALK fusion and MET amplification as molecular biomarkers and therapeutic targets in advanced lung adenocarcinomas in the Lung Cancer Mutation Consortium. J Thorac Oncol 6(6): S291
Yamamoto N, Tamura T, Fukuoka M, Saijo N (1999) Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol 15(4):737–741. https://doi.org/10.3892/ijo.15.4.737
Yang P (2011) Lung cancer in never-smokers: prognostic implications. J Thorac Oncol 6(6):S50
Yousefi M, Bahrami T, Salmaninejad A, Nosrati R, Ghaffari P, Ghaffari SH (2017) Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. Cell Oncol (dordr) 40(5):419–441. https://doi.org/10.1007/s13402-017-0345-5
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
All the authors contributed substantially to the study conception, design. Material preparation and data collection were performed by GG, BYA, FBB, AD, PG, UD, PFY, FÇŞ, BÇ, İÇ, AÖ, HŞC, EÇ, AI, ÖFÖ, AMT, MK, TŞ, YE, TK. Statistical analysis was performed by SK. The first draft of the manuscript was written by GG and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This study was conducted in accordance with the Declaration of Helsinki and approved by the institutional review boards at each of the participating centers.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Güner, G., Aktaş, B.Y., Başal, F.B. et al. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?. J Cancer Res Clin Oncol 149, 13271–13277 (2023). https://doi.org/10.1007/s00432-023-05190-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-05190-3